SHStefanie Hölsken

Stefanie Hölsken

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stefanie Hölsken has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond pharmacology: The mediating role of expectations in the experience of side effects in anxious patients treated with secukinumab

    by Senta Mühlhaus, Frederik Krefting, Daniela Bese, Manfred Schedlowski, Wiebke Sondermann, Stefanie Hölsken

  • Open Access

    Four Weeks of Biologic Treatment are Sufficient to Normalize Blunted HPA-Axis Activity and Significantly Improve Psychological Burden in Patients with Psoriasis

    by Frederik Krefting, Stefanie Hölsken, Paraskevi Savvidou, Lukas Sollfrank, Carl Maximilian Thielmann, Jan-Malte Placke, Maurice Moelleken, Lennart Ocker-Serger, Lea Jessica Albrecht, Joachim Dissemond, et al.

    Purpose: Psoriasis is associated with substantial psychological burden and dysregulation of endocrine pathways, including the hypothalamic-pituitary-adrenal (HPA) axis. Although biologic therapies improve skin disease, early changes in psychological burden and HPA-axis activity remain insufficiently characterized. This study addresses this scientific gap. Patients and Methods: This prospective observational study analyzed data from n = 50 patients with moderate-to-severe psoriasis who were assessed at baseline and after 4 weeks of biologic therapy, and from n = 50 matched healthy controls evaluated at baseline. Primary psychological outcomes were depressive symptoms, anxiety, and perceived stress, measured using Beck’s Depression Inventory (BDI), the State-Trait Anxiety-Depression Inventory (STADI), and the Perceived Stress Scale (PSS). Plasma cortisol levels were analyzed in a sampling-time-matched subgroup of n = 25 patients and n = 25 healthy controls. Results: At baseline, patients with psoriasis showed pronounced psychological distress compared with healthy controls, including higher depressive symptoms, state and trait anxiety, state and trait depression, and perceived stress. After 4 weeks of biologic treatment, patients with psoriasis showed significant improvements in BDI, STADI state anxiety, STADI trait anxiety, and PSS scores (all p ≤ 0.002). By week 4, BDI scores, trait anxiety, and perceived stress were no longer different between patients and controls according to Bonferroni-adjusted tests. Baseline plasma cortisol in patients with psoriasis was lower than in controls (p =0.015) and increased significantly after 4 weeks (p =0.008), no longer differing from healthy controls (p =0.839). Concurrently, PASI decreased from 16.9 to 7.2 after 4 weeks of biologic therapy (p < 0.001). Conclusion: After only 4 weeks of biologic therapy, patients with psoriasis showed marked improvement in psychological burden, and plasma cortisol shifted from a reduced baseline level toward the range observed in healthy controls, consistent with early normalization of HPA-axis activity.

  • Open Access

    Experimental Approach to Inducing Anti-Histaminergic Placebo Effects: A Randomized Controlled Trial in Healthy Volunteers

    by Stefanie Hölsken, Eva Holubek, Frederik Krefting, Senta Mühlhaus, Daniela Bese, Joachim Dissemond, Oliver Pfaar, Winfried Rief, Manfred Schedlowski, Wiebke Sondermann

    Introduction: Allergies are an increasingly widespread health problem and prior evidence suggests that psychological factors are involved in their occurrence and alleviation. This study aimed to investigate how placebo treatment can reduce type-I allergic symptoms in a skin prick test in healthy volunteers. Methods: Healthy volunteers of all genders were included in the study (N = 88) and were randomized into three groups: (i) a classically conditioned group receiving the anti-histaminergic drug cetirizine as unconditioned stimulus (US) and a novel gustatory stimulus as conditioned stimulus (CS), (ii) a context-control group receiving cetirizine (US) and water as CS and (iii) an open-label placebo group. In the spirit of the ethical application of placebo, participants were not blinded with regard to the study question. Histamine skin prick tests were conducted at baseline, after five acquisition trials, before evocation, as well as after three and five evocation trials. Self-rated itch and wheal size measurements served as outcome parameters. Results: Itch was significantly reduced after medication and (open) placebo intake. Wheal size was only reduced significantly after medication intake during acquisition. After 9 days of washout, itch ratings were lower in participants who had received open-label placebo compared to those who had initially received cetirizine. During the evocation week, the decline in wheal size did not reach statistical significance and there was no significant differential effect of group allocation. Reported expectations of symptom relief at the last visit correlated positively with reductions of wheal size, but results were substantially influenced by outliers. Expectations of relief could partially be explained by participants’ prior experiences and group allocation. Conclusion: Participants of all groups experienced a reduction in itch, while wheal size was only reduced in those participants with high expectations. These expectation effects align with prior research but should be carefully tested in future studies. Taken together, these results support the theory of differing mechanisms between patients with lived experience and healthy participants. Future studies should investigate the underlying neuropsychological mechanisms of expectation-induced anti-histaminergic effects.

  • Open Access

    Baseline Pathological Liver Function Tests in Patients With Psoriasis Support the Indication for Systemic Therapy Rather Than Being a Reason Against It: A Real-World Analysis

    by Frederik Krefting, Cosima Scheib, Sven Benson, Stefanie Hölsken, Jan-Malte Placke, Heiner Wedemeyer, Wiebke Sondermann

    Purpose: Modern systemic therapies offer a high probability of significant improvement for psoriasis. However, elevated liver function tests (LFTs) may cause physicians to be reluctant to initiate systemic treatment. Especially considering the already increased risk of liver disease in patients with psoriasis, clinicians are often concerned about potential further liver damage caused by systemic therapies. The aim of this study was to provide real-world evidence to address this issue. Patients and methods: This study retrospectively analyzed the treatment courses of N = 278 patients with psoriasis who received systemic anti-psoriatic therapy with secukinumab, ixekizumab, adalimumab, or apremilast in clinical routine. The cohort was divided into two subgroups based on normal or elevated LFTs prior to the start of therapy. AST, ALT, and GGT levels as well as Fibrosis-4 score (FIB-4) were measured at baseline, after 3 months, and after 6 months of therapy. Results: The subgroup of patients with elevated LFTs had a higher mean PASI (Psoriasis Area and Severity Index), were more likely to be male, and had a higher prevalence of metabolic syndrome comorbidities compared to the subgroup with normal LFTs. During the follow-up period, there were no significant changes in LFTs and FIB-4 for the subgroup with normal LFTs at baseline. In the group of patients with initially elevated LFTs, all LFTs decreased significantly over time, whereas FIB-4 scores demonstrated no significant change. Drug survival, discontinuation rates, and PASI-75 response did not significantly differ between subgroups. Conclusion: This study provides real world evidence that systemic therapy with secukinumab, ixekizumab, adalimumab, or apremilast does not present a general risk, but rather an opportunity for patients with psoriasis with elevated LFTs at baseline.


  • Open Access

    Shaping Treatment Expectation to Optimize Efficacy of Interleukin 17A Antagonist Secukinumab in Psoriasis Patients

    by Stefanie Hölsken, Frederik Krefting, Senta Mühlhaus, Daniela Bese, Manfred Schedlowski, Wiebke Sondermann

    Purpose: Patients’ treatment expectations significantly influence the effectiveness of medical and pharmacological treatments. This clinical proof-of-concept study aimed to enhance treatment outcomes by targeting positive treatment expectations of psoriasis patients beginning systemic anti-psoriatic therapy with secukinumab, an interleukin (IL)-17A antagonist. Patients and Methods: We randomly assigned patients to three groups: a treatment as usual (TAU) group receiving the standard 300mg dose of secukinumab, a dose-control (DC) group with 75% dose reduction and an experimental (EXP) group receiving the same reduced dose along with a “cover story” designed to positively influence treatment expectations. We evaluated skin symptoms using the Psoriasis Area and Severity Index (PASI), the Dermatology Life Quality Index (DLQI), perceived itch, mood and plasma IL-17A levels at baseline and at 1, 2, 3, 4, 8, 12, and 16 weeks post intervention. Results: The study included N = 120 patients (average age = 45.78 years, 34% female). A high baseline expectation level (8.1 of 10 points) was observed across all groups which could not be further increased by the EXP-group’s “cover story”. The EXP and DC groups did not differ with regard to reaching 75% improvement in PASI scores (PASI75), a DLQI score of 0 or 1 or at least 4 points improvement in itch. Over time, the EXP-group showed a faster decline in PASI scores and anxiety symptoms compared to the DC-group, but less improvement in quality of life. IL-17A levels significantly increased throughout the treatment, with no significant differences between groups despite the 75% dose reduction. Conclusion: This study demonstrates an attempt to modify patients’ treatment expectations to enhance the effectiveness of pharmacological therapy with secukinumab in psoriasis patients. However, verbal suggestion alone did not significantly improve clinical outcomes, suggesting that future studies should explore alternative approaches to leverage placebo effects to the benefit of patients with psoriasis.


  • Open Access

    “I Was Almost in Disbelief” - Qualitative Analysis of Experiences and Expectations Among Psoriasis Patients Undergoing Biologic Treatment with Secukinumab

    by Stefanie Hölsken, Carina Benthin, Frederik Krefting, Senta Mühlhaus, Yvonne Nestoriuc, Manfred Schedlowski, Wiebke Sondermann

    Purpose: Psoriasis is a highly debilitating chronic inflammatory disease. Increased understanding of its pathophysiology has enabled development of targeted treatments such as biologics. Several medical treatments have been shown to be influenced by patients’ experiences and expectations. However, only little is known about patients’ experiences with and expectations towards biologics. Our objectives were to identify patients’ treatment experiences and treatment expectations and assess their trajectories over the course of treatment with the IL-17A inhibitor secukinumab. Moreover, we aimed to document effects of psoriasis, factors that influence symptomatology, and prior treatment experiences. Patients and Methods: We conducted semi-structured interviews with n = 24 patients with moderate-to-severe plaque psoriasis and employed a qualitative content analysis to derive thematic and evaluative codes. Findings were validated via peer debriefings with experienced dermatologists. Results: Patients reported burdensome physical and psychological psoriasis symptoms and identified factors that can improve or worsen symptomatology, including stress and self-efficacy. Prior treatment experiences were mostly negative. Past barriers to effective treatment included time constraints or limited access. Concerning secukinumab, patients initially expected complete to partial remission of symptoms and occurrence or absence of side effects. Closer inspection of expectations and experiences revealed three trajectories. For most patients, initial expectations were met and future expectations remained unchanged. For the other patients, however, the experience did not match their initial expectation. One group then adapted their future expectations according to their experience, while the other group did not. Conclusion: To our knowledge, this is the first qualitative study to assess expectations towards treatment effectiveness and side effects, their trajectories, and interplay with experiences among psoriasis patients. Our findings highlight the value of further research on the subject in order to optimize care for psoriasis patients and to learn more about the trajectories and influence of treatment expectations in general. Plain Language Summary: Patients’ expectations towards a certain treatment can influence how well it will work and whether side effects occur or not. Such effects have been shown for a wide range of conditions, including dermatological ones. For patients suffering from psoriasis, a chronic inflammatory skin disease, modern biologics offer promising treatment options. Therefore, modern biologics are likely associated with high expectations by patients. Yet, the roles of treatment expectations and the experiences of patients undergoing biologic treatment have only received little attention to date. With this qualitative study, we aimed to understand patients’ perspectives on these treatments, the symptoms they suffer from, expectations towards treatment effectiveness and side effects as well as treatment experiences in the past and over the course of treatment with a modern biologic. To this end, we conducted and transcribed interviews with 24 patients after several months of biologic treatment. We then analyzed interview transcripts to determine underlying categories and summarized these in a common framework. We found that patients’ debilitating physical and psychological symptoms were often not well controlled in past treatments. Still, patients had positive expectations with regard to biologic treatment. For a large group of patients, their actual experiences met their expectations, leaving them with unchanged expectations for the future. Another important finding was the good understanding of factors influencing their symptomatology that patients had, like stress and self-efficacy. The reported findings may aid doctors in their clinical work, to further improve care for psoriasis patients.


  • Alleviating allergic skin responses - Preliminary data of a conditioning and open label placebo paradigm

    by Stefanie Hölsken, Eva Holubek, Frederik Krefting, Senta Mühlhaus, Manfred Schedlowski, Wiebke Sondermann